Publication Name	World Journal of Hepatology
Manuscript ID	90058
Country	Egypt

Received	2023-11-21 21:37
Peer-Review Started	2023-11-21 21:39
First Decision by Editorial Office Director	2024-01-24 20:44
Return for Revision	2024-01-24 20:44
Revised	2024-02-08 16:40
Publication Fee Transferred
Second Decision by Editor	2024-03-26 01:24
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-03-26 04:26
Articles in Press	2024-03-26 04:26
Edit the Manuscript by Language Editor	2024-03-18 05:30
Typeset the Manuscript	2024-04-16 01:10
Publish the Manuscript Online	2024-04-24 08:35

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
Manuscript Source	Invited Manuscript
All Author List	Mohamed Wishahi
ORCID	Author(s) ORCID Number Mohamed Wishahi http://orcid.org/0000-0002-4559-619X
Funding Agency and Grant Number
Corresponding Author	Mohamed Wishahi, MD, PhD, Professor, Surgical Oncologist, Department of Urology, Theodor Bilharz Research Institute , Embaba, Giza, Cairo 12411, Egypt. moh.weshahy@gmail.com
Key Words	Programmed cell death protein-ligand 1; Erdafitinib; Liver cancer; Fibroblast growth factor receptor inhibitors; Checkpoint inhibitors; Bladder cancer; Metastases
Core Tip	The promising results of first-line treatment of advanced and metastatic urothelial carcinoma with programmed cell death protein 1 blockades with single or combined agents, indicate a new concept in the treatment of advanced, metastatic, and recurrent hepatic and gastrointestinal carcinomas. Cancer immunotherapy as a first-line treatment will improve overall survival and quality of life. At present, cancer immunotherapy as first-line treatment in invasive carcinomas or as second-line treatment in recurrent or metastatic carcinoma following the standard chemotherapy is applied on a case-by-case basis.
Publish Date	2024-04-24 08:35
Citation	Wishahi M. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept. World J Hepatol 2024; 16(4): 490-493
URL	https://www.wjgnet.com/1948-5182/full/v16/i4/490.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i4.490

Full Article (PDF)	WJH-16-490-with-cover.pdf
Manuscript File	90058_Auto_Edited-HZ-WangTQ-YJP.docx
Answering Reviewers	90058-Answering reviewers.pdf
Audio Core Tip	90058-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	90058-Conflict-of-interest statement.pdf
Copyright License Agreement	90058-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90058-Language certificate.pdf
Peer-review Report	90058-Peer-review(s).pdf
Scientific Editor Work List	90058-Scientific editor work list.pdf
CrossCheck Report	90058-CrossCheck report.pdf